Efficient prime editing in mouse brain, liver and heart with dual AAVs
Top Cited Papers
Open Access
- 4 May 2023
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 42 (2) , 253-264
Abstract
Realizing the promise of prime editing for the study and treatment of genetic disorders requires efficient methods for delivering prime editors (PEs) in vivo. Here we describe the identification of bottlenecks limiting adeno-associated virus (AAV)-mediated prime editing in vivo and the development of AAV-PE vectors with increased PE expression, prime editing guide RNA stability and modulation of DNA repair. The resulting dual-AAV systems, v1em and v3em PE-AAV, enable therapeutically relevant prime editing in mouse brain (up to 42% efficiency in cortex), liver (up to 46%) and heart (up to 11%). We apply these systems to install putative protective mutations in vivo for Alzheimer’s disease in astrocytes and for coronary artery disease in hepatocytes. In vivo prime editing with v3em PE-AAV caused no detectable off-target effects or significant changes in liver enzymes or histology. Optimized PE-AAV systems support the highest unenriched levels of in vivo prime editing reported to date, facilitating the study and potential treatment of diseases with a genetic component.Keywords
Funding Information
- National Heart and Lung Institute (R01HL148769)
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01AI142756)
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118062)
- U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
- Howard Hughes Medical Institute (Liu)
- Bill and Melinda Gates Foundation (Liu)
This publication has 99 references indexed in Scilit:
- Mismatch Repair Genes Mlh1 and Mlh3 Modify CAG Instability in Huntington's Disease Mice: Genome-Wide and Candidate ApproachesPLOS Genetics, 2013
- Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary VectorsHuman Gene Therapy, 2011
- Several rAAV Vectors Efficiently Cross the Blood–brain Barrier and Transduce Neurons and Astrocytes in the Neonatal Mouse Central Nervous SystemMolecular Therapy, 2011
- Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neuronsNature Neuroscience, 2010
- Effect of Genome Size on AAV Vector PackagingMolecular Therapy, 2010
- The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans‐splicing reactionFEBS Letters, 2009
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9Nature Genetics, 2005
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003